Hair Loss News and Research

RSS

FDA approves new treatment for adults with metastatic bladder cancer

The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.

12 Apr 2019

Scientists aim to minimize or eliminate hair loss during cancer treatment

SCIENTISTS at the University of Huddersfield aim to minimize or eliminate completely, the hair loss that is one of the most distressing side-effects of cancer treatment.

11 Apr 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019

Study finds gene variant which causes hairlessness in dogs

Hairlessness in dogs can be the result of deliberate breeding or, in certain breeds, a defect. A recent study completed at the University of Helsinki describes a gene variant in the SGK3 gene, which causes hairlessness in Scottish Deerhounds.

2 Apr 2019

World's first scalp cooling research center to benefit cancer sufferers

A MAJOR global healthcare technology company, which has a long-standing research history with the University, is to create a dedicated research center to benefit cancer sufferers.

27 Feb 2019

PAXMAN to showcase latest scalp cooling system at Arab Heath 2019

British scalp cooling expert, PAXMAN will showcase the latest model of the PAXMAN Scalp Cooling System at Arab Health 2019.

From Paxman 10 Jan 2019

Mass spectrometry throws light on old case of intentional heavy metal poisoning

In 1994, Chinese university student Zhu Ling began experiencing stomach pain, hair loss and partial paralysis.

14 Dec 2018

Russian researchers develop novel combined action drug for cancer diagnostics and treatment

Russian researchers announced the development of a combined action drug based on ionizing radiation and bacterial toxin. Their total effect appeared to be 2,200 times stronger compared to that exerted by the radiation and toxin, separately.

4 Dec 2018

New first-line treatment for peripheral T-cell lymphoma approved by FDA

The U.S. Food and Drug Administration today expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

16 Nov 2018

Geneticists decipher new gene responsible for rare form of hair loss

Hypotrichosis simplex leads to progressive hair loss already in childhood. A team of researchers led by human geneticists at the University Hospital of Bonn has now deciphered a new gene that is responsible for this rare form of hair loss.

6 Nov 2018

Cooling therapies may offer best protection against adverse effects of taxane-based chemotherapy

Due to their broad antitumor activity that inhibits the function of microtubules, taxanes are common chemotherapeutic agents utilized for the management of multiple cancer types from breast to prostate. Unfortunately, the frequency of their use is equally matched by the rates of expected and well known side effects.

2 Nov 2018

Scientists describe novel conjugates made from antibodies and protein inhibitor

Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects--especially when treating tumors. In the journal Angewandte Chemie, scientists have now described novel conjugates made from antibodies and a kinesin spindle protein inhibitor.

31 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Study finds differences in side-effects experienced by male and female OG cancer patients

Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomized controlled clinical trials of first line chemotherapy in oesophagogastric cancer, finding significant differences in a number of important side-effects experienced by male and female patients.

19 Oct 2018